Fig. 1 · Structure

Documents & Downloads

Laquinimod (ABR-215062)

Cat. No. A11128 CAS 248281-84-7
Laquinimod (ABR-215062) is a potent immunomodulator.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
NF-κB  

Laquinimod (ABR-215062) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Laquinimod (ABR-215062) from 3 published references.

Laquinimod (ABR-215062) In Vitro Studies

Human microglia cultures were pretreated with Laquinimod before LPS activation. Laquinimod attenuated the elevation of TNF-α in conditioned media compared with LPS-activated microglia. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Laquinimod and TNF-α Release in Human Microglia

Cell-based study · Human microglia [1]

Human microglia cultures were pretreated with Laquinimod before LPS activation. Laquinimod attenuated the LPS-induced elevation of TNF-α measured in conditioned media compared with LPS-activated microglia.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TNF-α measured from the conditioned media of cellsReported result human (C) or mouse (D) microglia elevated this cytokine upon LPS activation and this was attenuated by laquinimod[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1–20 μmol/L
Exposure duration
pretreated with different concentrations (0.1–20 μmol/L) of laquinimod (LQ) for 24 h following which LPS was used to activate the cells for 24 h
Method
added to microglia cultures
Co-treatment
Other interventions in this design: lipopolysaccharide 100 ng/mL. Compound effect isolated by the comparison: compared to LPS-activated microglia.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Laquinimod

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Evaluation of the impact of laquinimod on microglia activation in culture (S10); Figure 1 legend (S93, S95)

TNF-α measured from the conditioned media of cells: TNF-α measured from the conditioned media of cells; comparator: LPS-activated microglia — Figure 1 legend (S95)

Laquinimod (ABR-215062) In Vivo Studies

In male mice undergoing cuprizone feeding, daily oral Laquinimod reduced demyelination scores compared with untreated mice. In another study under cuprizone feeding, Laquinimod significantly reduced the density of caspase-3-positive apoptotic cells in the corpus callosum compared with vehicle controls. In immunized DBA/1 mice, daily Laquinimod by oral gavage prevented EAE development compared with water vehicle. [2,3]

Laquinimod and Cuprizone-Induced Demyelination in Mice

Animal study · male C57BL/6J mice; cuprizone-induced demyelination [2]

Male mice with cuprizone-induced demyelination received Laquinimod orally each day from the beginning of cuprizone feeding. Demyelination scores were lower at both doses than in untreated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
semi-quantitative scores for demyelinationReported result untreated mice (score 2.8 ± 0.4); lower (score 1.8 ± 0.8, p < 0.01) or higher LAQ dose (score 0.6 ± 0.3, p < 0.001)[2]

Conditions shared by the study groups

Route
orally
Treatment course
daily; from the beginning of the cuprizone feeding; 6 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Laquinimod 5 and 25 mg/kgControl mice received vehicle.untreated mice (score 2.8 ± 0.4); lower (score 1.8 ± 0.8, p < 0.01) or higher LAQ dose (score 0.6 ± 0.3, p < 0.001)[2]
Laquinimod 5 and 25 mg/kg
Model: male C57BL/6J mice; cuprizone-induced demyelination
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Laquinimod

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Test compounds and formulations (S1, S4); Materials and methods > Mice (S7); Materials and methods > Cuprizone treatment (S11); Materials and methods > Histopathology (S15); Results > LAQ inhibits cuprizone-induced demyelination in a dose-dependent manner (S85, S90); Fig. 2 legend (S142)

semi-quantitative scores for demyelination: semi-quantitative scores for demyelination; comparator: Control mice received vehicle. — Results > LAQ inhibits cuprizone-induced demyelination in a dose-dependent manner (S90); Fig. 2 legend (S142)

Laquinimod 5 and 25 mg/kg · Materials and methods > Test compounds and formulations (S1); Results > LAQ inhibits cuprizone-induced demyelination in a dose-dependent manner (S85, S90)

Laquinimod and EAE Development in Mice

Animal study · DBA/1 mice; n = 6/group [3]

DBA/1 mice received Laquinimod at 25 mg/kg by daily oral gavage starting on the day of immunization. Treatment prevented EAE development compared with water vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EAE disease courseReported result oral laquinimod treatment prevented development of EAE in DBA/1 mice[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily; starting from the day of immunization
Vehicle
purified water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Laquinimod 25 mg/kgvehicle (water, n = 6/group)oral laquinimod treatment prevented development of EAE in DBA/1 mice[3]
Laquinimod 25 mg/kg
Model: DBA/1 mice; n = 6/group
Methods and source locations

Compound reported in the paper: Laquinimod

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Laquinimod reverses EAE and inhibits pathogenic T cell immune responses (S3); Materials and Methods > EAE Induction (S57); Materials and Methods > Laquinimod treatment (S63); Figure 1 legend (S107, S114)

EAE disease course: EAE disease course; comparator: vehicle (water, n = 6/group) — Results > Laquinimod reverses EAE and inhibits pathogenic T cell immune responses (S3); Figure 1 legend (S114)

Laquinimod 25 mg/kg · Results > Laquinimod reverses EAE and inhibits pathogenic T cell immune responses (S3); Materials and Methods > Laquinimod treatment (S63); Figure 1 legend (S107)

Laquinimod and Apoptotic Cell Density in the Corpus Callosum

Animal study · male C57BL/6J mice; LAQ-treated mice (n = 10); controls (n = 10) [2]

Male mice undergoing cuprizone feeding received Laquinimod orally at 25 mg/kg daily from the beginning of feeding. The density of caspase-3-positive apoptotic cells in the corpus callosum was significantly lower in Laquinimod-treated mice than in vehicle controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
density of caspase-3-positive apoptotic cells in the corpus callosumReported result significantly lower in LAQ-treated mice than in controls (37 ± 26 caspase-3-positive apoptoses per mm2 vs. 98 ± 28 caspase-3-positive apoptoses per mm2; p < 0.001)[2]

Conditions shared by the study groups

Route
orally
Treatment course
daily; from the beginning of the cuprizone feeding; 1 week
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Laquinimod 25 mg/kgControl mice received vehicle.significantly lower in LAQ-treated mice than in controls (37 ± 26 caspase-3-positive apoptoses per mm2 vs. 98 ± 28 caspase-3-positive apoptoses per mm2; p < 0.001)[2]
Laquinimod 25 mg/kg
Model: male C57BL/6J mice; LAQ-treated mice (n = 10); controls (n = 10)
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Laquinimod

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Test compounds and formulations (S1, S4); Materials and methods > Mice (S7); Materials and methods > Histopathology (S16); Results > LAQ reduces cuprizone-induced apoptoses (S80, S84); Fig. 1 legend (S139)

density of caspase-3-positive apoptotic cells in the corpus callosum: density of caspase-3-positive apoptotic cells in the corpus callosum; comparator: Control mice received vehicle. — Results > LAQ reduces cuprizone-induced apoptoses (S84)

Laquinimod 25 mg/kg · Materials and methods > Test compounds and formulations (S1); Results > LAQ reduces cuprizone-induced apoptoses (S80, S84); Fig. 1 legend (S139)

Specifications

Manufacturer Adooq Bioscience
CAS Number 248281-84-7
Formula C19H17ClN2O3
Molecular Weight 356.8
Synonyms ABR-215062
SMILES
CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 60 mg/mL (168.16 mM)
Water Insoluble
Ethanol 1 mg/mL (2.8 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Laquinimod (ABR-215062) Research References

  1. [1] Mishra MK, Wang J, Keough MB, et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol (2014). PMID: 25356411 DOI: 10.1002/acn3.67 Source material
  2. [2] Brück W, Pförtner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol (2012). PMID: 22766690 DOI: 10.1007/s00401-012-1009-1 Source material
  3. [3] Schulze-Topphoff U, Shetty A, Varrin-Doyer M, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012). PMID: 22479444 DOI: 10.1371/journal.pone.0033797 Source material

Added to your cart

View Cart Checkout
Loading...